Henry Schein Inc
HSIC
ISIN null / Valor 83527
Henry Schein Inc
UMushroom community rating:
About company
Henry Schein Inc., a Fortune 500 company and member of the S&P 500 index, is a prominent provider of health care solutions, catering to over 1 million customers worldwide. Headquartered in Melville, New York, the company operates in 33 countries and territories, employing approximately 26,000 people. Henry Schein offers a comprehensive range of business, clinical, technology, and supply chain solutions designed to enhance the efficiency and effectiveness of office-based dental and medical practitioners, as well as dental laboratories, government and institutional health care clinics, and other alternate care sites. The company's extensive product portfolio includes over 300,000 branded and corporate brand products, distributed through a centralized and automated network. In 2023, Henry Schein reported sales of $12.3 billion, reflecting a consistent growth trajectory since its public listing in 1995. The company is known for its integrated sales and marketing strategy, which is supported by targeted direct marketing efforts.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (15.11.2025):
Henry Schein Inc reported its fourth-quarter 2024 financial results along with full‐year 2024 outcomes, demonstrating robust operational performance and strategic realignment. The company highlighted strong EPS performance, sales growth across its reportable segments, enhanced operating cash flow and EBITDA, along with key restructuring and share repurchase initiatives. Additionally, the report outlined updated organizational structures and provided guidance for 2025, reinforcing its commitment to high-growth, high-margin business segments.
Q4 Financial Performance
In the fourth-quarter 2024, Henry Schein Inc delivered GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19, reflecting significant improvement compared to the prior year. Total net sales reached $3.2 billion, marking a 5.8% increase driven by internal sales growth, acquisitions, and currency effects. Operating cash flow was robust at $204 million, and Adjusted EBITDA rose to $270 million.
Full-Year 2024 Highlights
For full-year 2024, the company reported total net sales of $12.7 billion, up 2.7% over 2023. GAAP net income was $390 million (or $3.05 per share) with non-GAAP net income at $605 million (or $4.74 per share). Operating cash flow increased to $848 million, which was $348 million higher than 2023, and Adjusted EBITDA reached $1,061 million.
Guidance and Strategic Initiatives
Looking ahead, Henry Schein Inc expects 2025 non-GAAP diluted EPS to be in the range of $4.80 to $4.94, coupled with mid-single digit Adjusted EBITDA growth. The company also introduced new reportable segments and updated its organizational structure to provide more meaningful insights for investors as it builds on its BOLD+1 Strategic Plans for 2022–2024 and 2025–2027.
Restructuring and Share Repurchases
During fourth-quarter 2024, the company incurred $37 million in restructuring costs, with anticipated annual run-rate savings of over $80 million scheduled from activities in the third and fourth quarters. Additionally, Henry Schein Inc repurchased approximately 1.1 million shares for $75 million during Q4, with overall full-year repurchases amounting to roughly $385 million, reinforcing its commitment to shareholder value.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
8409 M
Market cap (USD)
1,499,868
Daily traded volume (Shares)
70.1 / 68.84
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
